title: Dalfampridine in hereditary spastic paraplegia: a prospective, open study.
abstract: Our aim was to support the use of dalfampridine as a treatment for patients affected with hereditary spastic paraplegia (HSP). We performed a prospective, uncontrolled, proof of concept, open trial. We included 12 HSP patients defining the total group (TG) who received dalfampridine 10 mg twice daily for 2 weeks. Efficacy assessment was based on walking ability improvement. The Timed-25-Foot Walk Test, the Spastic Paraplegia Rating Scale (SPRS), and the 12-item Multiple Sclerosis Walking Scale (MSWS-12) were performed before and after treatment. Safety assessment was based on adverse events occurrence. A significant improvement in SPRS (p = 0.0195) and MSWS-12 (p = 0.0429) was noted after treatment in the TG. No serious adverse events were noted. This interventional study provides encouraging results supporting the use of dalfampridine in HSP.
authors: Département de Neurologie, CHRU de Besançon, Besançon, France.
authors: Matthieu
authors: M
authors: Béreau
authors: Mathieu
authors: M
authors: Anheim
authors: Jean-Baptiste
authors: JB
authors: Chanson
authors: Grégory
authors: G
authors: Tio
authors: Andoni
authors: A
authors: Echaniz-Laguna
authors: Christel
authors: C
authors: Depienne
authors: Nicolas
authors: N
authors: Collongues
authors: Jérôme
authors: J
authors: de Sèze
mesh_terms: D015761:4-Aminopyridine / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000470:Alkaloids; D000704:Analysis of Variance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D026902:Potassium Channel Blockers / Q000627:therapeutic use*; D011446:Prospective Studies; D012720:Severity of Illness Index; D015419:Spastic Paraplegia, Hereditary / Q000188:drug therapy* / Q000503:physiopathology; D016138:Walking / Q000502:physiology
chemical_list: D000470:Alkaloids; D026902:Potassium Channel Blockers; C110131:Wilcox compound; D015761:4-Aminopyridine